Financial Performance - The company reported a net profit attributable to shareholders of RMB 51,894,845.59 for the year 2024, with a profit distribution plan proposing a cash dividend of RMB 5.00 per 10 shares, totaling RMB 39,959,266.50, which represents 77.00% of the net profit[10]. - The estimated total cash dividends for 2024, including interim dividends and special dividends, is RMB 119,179,342.50, which exceeds the net profit by 229.66%[10]. - The company achieved operating revenue of CNY 272.37 million in 2024, an increase of 7.38% compared to the previous year[30]. - Net profit attributable to shareholders reached CNY 51.89 million, up 9.69% year-on-year; net profit excluding non-recurring items was CNY 46.74 million, a 24.46% increase[30]. - Basic earnings per share were CNY 0.65, reflecting an 8.33% growth; diluted earnings per share were CNY 0.64, up 10.34%[31]. - Total assets increased by 1.70% compared to the beginning of the reporting period, while net assets attributable to shareholders rose by 1.73%[31]. - The company reported a net cash flow from operating activities of CNY 53.41 million, down 35.61% from the previous year[28]. - The company reported a disposal loss of non-current assets amounting to 10.52 million RMB in 2024, compared to a gain of 0.66 million RMB in 2023[35]. - The company’s total non-recurring gains and losses amounted to 51.54 million RMB in 2024, down from 97.57 million RMB in 2023[36]. Dividend Distribution - The total number of shares eligible for dividend distribution is 79,918,533, after excluding 1,237,067 shares held in the repurchase account[10]. - The company plans to maintain its dividend distribution strategy despite potential fluctuations in share capital due to repurchases[11]. - The proposed cash dividend for the first half of 2024 is RMB 5.00 per 10 shares, totaling RMB 39,632,429, which exceeds the net profit attributable to shareholders by 137.37%[197]. - The special cash dividend for 2024 is also set at RMB 5.00 per 10 shares, amounting to RMB 39,587,647, which is 92.60% of the net profit attributable to shareholders for the first three quarters of 2024[197]. - The company plans to distribute a cash dividend of RMB 5.00 per 10 shares to all shareholders, totaling RMB 39,959,266.50, which represents 77.00% of the net profit attributable to shareholders for the fiscal year 2024[199]. - The total expected cash dividend distribution for the fiscal year 2024 is RMB 119,179,342.50, accounting for 229.66% of the net profit attributable to shareholders[199]. - The cash dividend distribution will utilize 98.40% of the company's cumulative undistributed profits as of the end of fiscal year 2024[199]. - The company has revised its cash dividend policy to ensure that the annual profit distribution is at least 20% of the distributable profit for the year or 30% of the average annual distributable profit over the last three years[200]. Research and Development - The company is actively engaged in the research and development of new products, including various types of surgical staplers and cutting devices, which are currently under development[18]. - The company maintained a research and development investment ratio of 13.21% of operating revenue, a slight decrease from the previous year[29]. - The company invested in R&D, resulting in 52 new patent applications and 138 new authorizations, including 116 for core technology inventions[44]. - The company has established a research and development model centered on clinical insights and rapid iteration, conducting over ten domestic and international surgeon meetings to address clinical needs and enhance product innovation[56][57]. - The company is actively building a "Minimally Invasive Surgery Technology Innovation Alliance" with eight institutions, including Fudan University, to advance research and innovation in high-end medical devices[57]. - The company achieved a total R&D investment of ¥35,991,857.36, representing a 1.90% increase from the previous year[85]. - The proportion of total R&D investment to operating revenue decreased by 0.71 percentage points to 13.21%[85]. - The company applied for 53 new patents this year, bringing the total number of patents to 1,724, with 807 patents granted[83]. Market Expansion and Strategy - The company expanded its market presence, successfully obtaining 39 new overseas product registration certificates, bringing the total to 62 countries and regions covered[43]. - The company is actively expanding its marketing channels by integrating online branding with offline expansion strategies[61]. - The increasing prevalence of chronic non-communicable diseases in China is driving the demand for surgical staplers, with a growing focus on minimally invasive surgical techniques[62]. - The company is responding to national centralized procurement policies to better meet market demands and enhance brand influence through partnerships with hospitals and research institutions[59]. - The company is focused on improving product performance to reduce complications associated with stapler use, such as bleeding and leakage[70]. - The company is enhancing its dealer management system to improve service quality and compliance among distributors[59]. - The company plans to continue focusing on innovation and expanding its market presence in both domestic and international markets[30]. - The company will continue to drive dual domestic and international market development strategies, increasing market penetration and brand awareness to benefit more patients[142]. Corporate Governance - The company held three shareholder meetings in 2024, reviewing 12 proposals to ensure equal rights for all shareholders, especially minority shareholders[154]. - The company held 7 supervisory board meetings during the reporting period, reviewing 23 proposals[157]. - The independent directors actively participated in shareholder meetings and board meetings, ensuring the protection of minority shareholders' rights[156]. - The company has maintained independence from its controlling shareholders, with no instances of fund occupation or guarantees provided to them[158]. - The board committees operated within their defined authority, providing professional opinions for board decisions[157]. - The company disclosed information in compliance with regulations, ensuring transparency and equal access for all shareholders[158]. - The total number of shares held by the chairman and general manager remained unchanged at 20,978,130 and 20,934,000 respectively[165]. - The company implemented a restricted stock incentive plan, resulting in an increase of 81,618 shares for the secretary of the board[165]. Employee Management - The company has implemented a comprehensive talent management system, including performance evaluation and employee benefits, to enhance organizational effectiveness and support strategic goals[50]. - The company has a total of 254 employees, with 251 in the parent company and 3 in major subsidiaries[186]. - The employee composition includes 90 production personnel, 62 sales personnel, 54 technical personnel, 7 financial personnel, and 41 administrative personnel[187]. - The company provides various statutory benefits including pension, medical, unemployment, work injury, maternity insurance, housing fund, and paid leave[188]. - The company emphasizes a fair salary system based on job value assessment to attract and retain talent[188]. - The total hours of outsourced labor amounted to 18,394 hours, with total remuneration paid for outsourcing reaching 518,100 CNY[191]. - The company collaborates with external organizations for employee training, focusing on professional skills, occupational qualities, safety regulations, and corporate culture[189]. Risk Management - The company has detailed risk factors associated with its operations in the report, emphasizing the importance of understanding these risks for investors[7]. - The company faces challenges in cost management due to price reductions following centralized procurement, which may lead to market concentration among leading firms[63]. - The company faces risks related to R&D failures, talent retention, and market competition due to centralized procurement policies[95][98][99]. Production and Quality Control - The company emphasizes quality control, adhering to ISO13485 standards and implementing advanced automated production and testing equipment[92]. - The company is focusing on optimizing its quality management system and enhancing production efficiency through the implementation of a manufacturing execution system (MES)[46]. - The company has achieved full network coverage in its production workshops, integrating smart devices and upgrading existing equipment to enhance automation and digitalization, significantly reducing manual intervention and production costs[47]. - The company was awarded the title of "Suzhou Level Intelligent Workshop - Minimally Invasive Surgical Stapler Intelligent Manufacturing Workshop" during the reporting period, indicating a commitment to enhancing smart manufacturing capabilities[47]. Strategic Partnerships and Acquisitions - The company is exploring potential acquisitions to enhance its market position, with a budget of $100 million allocated for this purpose[168]. - A new strategic partnership was announced, expected to generate an additional $20 million in revenue over the next year[168].

天臣国际医疗科技股份有限公司2025 年第一季度报告 证券代码：688013 证券简称：天臣医疗 天臣国际医疗科技股份有限公司 2025 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 (一) 主要会计数据和财务指标 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、主要财务数据 1 / 17 单位：元 币种：人民币 项目 本报告期 上年同期 本报告期比上年同 期增减变动幅度(%) 营业收入 65,846,058.15 60,219,598.04 9.34 归属于上市公司股东的净利润 13,186,665.95 11,352,005.37 16.16 归属于上市公司股东的扣除非 经常性损益的净利润 11,066,061.56 11,011,201 ...

证券代码：688013 证券简称：天臣医疗 公告编号：2025-023 天臣国际医疗科技股份有限公司 第二届董事会第二十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 天臣国际医疗科技股份有限公司（以下简称"公司"）第二届董事会第二十五 次会议于2025年4月25日以现场结合通讯的方式召开。会议通知已于2025年4月15 日通过书面及电话等方式送达全体董事。本次会议由董事长陈望宇先生召集并主 持，应出席会议董事7名，实际出席会议董事7名，本次会议的召集、召开及审议 程序符合《中华人民共和国公司法》及《天臣国际医疗科技股份有限公司章程》 （以下简称"《公司章程》"）的相关规定。 二、董事会会议审议情况 会议经与会董事审议并书面表决通过了如下议案： 1、审议通过《关于公司<2024年年度总经理工作报告>的议案》 经审议，董事会认为：2024年总经理带领公司员工，协调各个部门展开工作， 在公司持续运营等方面继续发挥专业作用，维护公司与全体股东的合法权益，促 进公司稳健经营和规范运作。因此 ...

证券代码：688013 证券简称：天臣医疗 公告编号：2025-025 天臣国际医疗科技股份有限公司 关于 2024 年度利润分配方案及 2025 年中期分红规划的公 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股分配比例：每10股派发现金红利人民币5.00元（含税），不送红股，不以 资本公积金转增股本。 本次利润分配以实施权益分派股权登记日登记的总股本扣除公司回购专用证 券账户中的回购股份为基数，具体日期将在权益分派实施公告中明确。 在实施权益分派股权登记日前，公司总股本扣除公司回购专用证券账户中的 回购股份发生变动的，公司拟维持每股分配金额不变，相应调整分红总额，并将另行 公告具体调整情况，具体金额以实际派发情况为准。 公司未触及《上海证券交易所科创板股票上市规则（2024年4月修订）》（以 下简称《科创板股票上市规则》）第12.9.1条第一款第（八）项规定的可能被实施其他 风险警示的情形。 本次利润分配方案已经公司第二届董事会第二十五次会议和第二届监事会第 十八次会议审议通过，尚需提交公司2 ...

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.6500 | 0.6000 | 8.33 | 0.5400 | | 每股净资产（元） | 0 | 7.04 | -100 | 6.26 | | 每股公积金(元) | 4.99 | 5.09 | -1.96 | 4.98 | | 每股未分配利润(元) | 1.30 | 1.21 | 7.44 | 0.92 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 2.72 | 2.54 | 7.09 | 2.32 | | 净利润(亿元) | 0.52 | 0.47 | 10.64 | 0.43 | | 净资产收益率(%) | 9.09 | 8.75 | 3.89 | 8.37 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 5011.55万股，累计占流通股比： 61.76%，较上期变化： -165. ...

天臣医疗688013 时间: 2025年4月25日星期五 54.87分综合得分 较强 趋势方向 主力成本分析 19.20 元 5日主力成本 元 元 当日主力成本 19.06 18.76 元 20日主力成本 19.10 60日主力成本 周期内涨跌停 过去一年内该股 涨停 0次 跌停 0 次 技术面分析 19.95 中期压力位 17.40 中期支撑位 目前短线趋势不慎明朗，静待主力资金选择方向； 目前中期趋势不慎明朗，静待主力资金选择方向 K线形态 ★长下影★ 持续下跌后出现,有可能止跌回升在升势末期出现,须多加留意 19.26 短期压力位 18.68 短期支撑位 资金流数据 2025年04月25日的资金流向数据方面 | 主力资金净流入53.58万元 | | --- | | 占总成交额4% | | 超大单净流入0.00元 | | 大单净流入53.58万元 | | 散户资金净流出174.25万 | 关联行业/概念板块 医疗器械 -0.31%、医疗器械概念 -0.12%、微盘股 -0.05%等 （以上内容为自选股写手差分机完成，仅作为用户看盘参考，不能作为操作依据。） 风险提示：以上内容仅作为作者或者嘉宾的观点，不代 ...

天臣国际医疗科技股份有限公司 期货、衍生品交易管理制度 第一章 总则 第一条 为进一步规范天臣国际医疗科技股份有限公司(以下简称"公司"或 "本公司")的期货、衍生品交易行为及相关信息披露工作，加强对期货、衍生品 交易的管理，防范投资风险，健全和完善公司期货、衍生品交易的管理机制，确 保公司资产安全，根据《中华人民共和国公司法》《中华人民共和国证券法》《中 华人民共和国期货和衍生品法》《上市公司信息披露管理办法》《上海证券交易所 科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号 ——规范运作》《上海证券交易所上市公司自律监管指引第 5 号——交易与关联 交易》等法律法规和规范性文件及《天臣国际医疗科技股份有限公司章程》（以 下简称"《公司章程》"）的相关规定，结合公司实际情况，特制定本制度。 第二条 本制度所称期货是指以期货合约或者标准化期权合约为交易标的的 交易活动。衍生品是指期货交易以外的，以互换合约、远期合约和非标准化期权 合约及其组合为交易标的的交易活动。期货和衍生品的基础资产既可以是证券、 指数、利率、汇率、货币、商品等标的，也可以是上述标的的组合。 第三条 本制度适用于公司 ...

天臣国际医疗科技股份有限公司 关于开展商品期货和外汇套期保值业务的 可行性分析报告 一、开展期货和外汇套期保值业务的情况概述 （一）期货套期保值业务 1、开展商品期货套期保值业务的目的 公司开展商品期货套保值业务旨在降低螺纹钢市场价格波动对"天臣医疗研 发及生产基地一期建设项目"投资成本的影响，充分利用期货市场的套期保值功 能，有效控制价格风险，有利于增强财务稳健性。 2、套期保值品种 7、授权 在上述额度范围和期限内，董事会授权董事长负责具体实施套期保值业务 螺纹钢期货。 3、投入资金规模 公司拟进行期货套期保值业务，预计动用的保证金不超过1,000万元人民 币，预计任一交易日持有的最高合约价值不超过5,000万元人民币，在上述额度内 可循环滚动使用。在审批有效期内，任一时点的交易金额（含前述交易的收益进 行再交易的相关金额）不超过上述额度。 4、开展套期保值业务期间 自董事会审议通过后12个月内有效。 5、资金来源 自有资金，不涉及募集资金。 6、交易方式 公司开展商品期货套期保值交易场所为上海期货交易所，交易品种为螺纹 钢，交易工具为标准期货合约。上述交易类型符合《上海证券交易所上市公司自 律监管指引第 ...

重要内容提示： 证券代码：688013 证券简称：天臣医疗 公告编号：2025-022 天臣国际医疗科技股份有限公司 关于2025年度开展商品期货和外汇套期保值业务的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 业务期限：自董事会审议通过后的12个月内有效。 资金来源：公司自有资金，不涉及募集资金。 1 已履行的审议程序：该事项已经公司第二届董事会审计委员会2025年第二次会 议、第二届董事会第二十四次会议和第二届监事会第十七次会议审议通过，无需提交 股东大会审议。 相关风险提示：公司开展的商品期货和外汇套期保值业务遵循合法、审慎、安 全、有效的原则，不以投机为目的，有利于稳定公司的正常生产经营，但商品期货和 外汇套期保值业务操作仍存在一定的市场风险、资金风险、流动性风险、技术风险、 政策风险等，敬请投资者注意投资风险。 一、商品期货和外汇套期保值业务情况概述 交易目的：天臣国际医疗科技股份有限公司（以下简称"公司"）及子公司为降 低螺纹钢市场价格波动对"天臣医疗研发及生产基地一期建设项目"投资成本的影响， 及防范 ...

证券代码：688013 证券简称：天臣医疗 公告编号：2025-021 天臣国际医疗科技股份有限公司 第二届监事会第十七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 天臣国际医疗科技股份有限公司（以下简称"公司"）第二届监事会第十七次 会议（以下简称"本次会议"）于 2025 年 4 月 8 日以现场结合通讯的方式召开。 会议通知于本次会议召开前通过书面及电话等方式送达全体监事，全体监事一致 同意豁免本次监事会会议的通知期限。本次会议由监事会主席沈捷尔女士召集并 主持，应出席会议监事 3 人，实际出席会议监事 3 人。本次会议的召集、召开和 审议程序符合《中华人民共和国公司法》和《天臣国际医疗科技股份有限公司章 程》的有关规定。 二、监事会会议审议情况 会议经与会监事审议并书面表决通过了如下议案： 特此公告。 天臣国际医疗科技股份有限公司 监事会 2025年4月10日 经审核，监事会认为公司及合并范围内的子公司开展期货和外汇套期保值业 务，有利于降低原材料价格、外汇波动对公司经营业 ...